Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-2-21
pubmed:abstractText
O-(beta-hydroxyethyl)-rutosides (HR) is used to treat chronic venous disease and signs and symptoms of chronic venous insufficiency (CVI), varicose veins, and deep venous disease. This independent prospective controlled trial (a registry study) evaluates how the efficacy of HR at the local level (perimalleolar region) can be increased by the administration of a topical HR gel. The study is based on evaluation of microcirculatory variables in patients with severe CVI (ambulatory venous pressure, > 56 mm Hg) and venous microangiopathy. Patients are treated using 1 of the following 3 regimens: oral treatment with 1 g sachets of HR (2 g/d total) plus topical HR 2% gel applied 3 times daily at the internal perimalleolar region; oral treatment only (same dosage), or light elastic compression stockings. Laser Doppler skin flux at rest, skin flux at the perimalleolar region, and transcutaneous PO2 and PCO2 are measured at baseline and at the end of the treatment period. A comparable group of healthy individuals without treatment is observed for 8 weeks. In the treatment groups, flux is increased, PO2 is decreased, and PCO2 is increased compared with normal skin. At 4 and 8 weeks, the improvement in skin flux (which is decreased by all measurements), the increase in PO2, and the decrease in PCO2 (indicating microcirculatory improvement) are statistically significantly greater in the combined oral plus topical treatment group (P < .05). No adverse effects, tolerability problems, or compliance issues are noted. These results indicate an important role of HR in the treatment and control of CVI and venous microangiopathy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0003-3197
pubmed:author
pubmed:issnType
Print
pubmed:volume
59 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7S-13S
pubmed:meshHeading
pubmed-meshheading:18287162-Administration, Cutaneous, pubmed-meshheading:18287162-Administration, Oral, pubmed-meshheading:18287162-Adult, pubmed-meshheading:18287162-Blood Flow Velocity, pubmed-meshheading:18287162-Blood Gas Monitoring, Transcutaneous, pubmed-meshheading:18287162-Capillary Permeability, pubmed-meshheading:18287162-Cardiovascular Agents, pubmed-meshheading:18287162-Chronic Disease, pubmed-meshheading:18287162-Diabetic Angiopathies, pubmed-meshheading:18287162-Edema, pubmed-meshheading:18287162-Gels, pubmed-meshheading:18287162-Humans, pubmed-meshheading:18287162-Hydroxyethylrutoside, pubmed-meshheading:18287162-Laser-Doppler Flowmetry, pubmed-meshheading:18287162-Middle Aged, pubmed-meshheading:18287162-Prospective Studies, pubmed-meshheading:18287162-Registries, pubmed-meshheading:18287162-Severity of Illness Index, pubmed-meshheading:18287162-Skin, pubmed-meshheading:18287162-Stockings, Compression, pubmed-meshheading:18287162-Time Factors, pubmed-meshheading:18287162-Treatment Outcome, pubmed-meshheading:18287162-Venous Insufficiency, pubmed-meshheading:18287162-Venous Pressure
pubmed:articleTitle
O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study.
pubmed:affiliation
Department of Biomedical Sciences, Chieti-Pescara University, and the San Valentino Vascular Screening Project, Italy. Cardres@abol.it
pubmed:publicationType
Journal Article, Comparative Study, Controlled Clinical Trial